Capricor Therapeutics, Inc.

NASDAQ:CAPR

Biotechnology

Healthcare
$8.03 -0.50%

-$0.14 today

Market cap
$465.03M
Beta
0.37
P/E (TTM)
-13.9
EPS (TTM)
-$2.00
52W Low $4.30High $40.37

Volume 8.33M

Average 1.08M

CAPR Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Capricor Therapeutics, Inc.NASDAQ: CAPR

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures grows, but more slowly than its trailing trend

Q1 FY2026 capital expenditures of $10.75M (cash outflow) rose 842.5% year over year, behind the +958.6% change in trailing-twelve-month capital expenditures. Sequentially, it rose 109.7% from the prior quarter. Over 3 fiscal years it compounded at -4.7% a year.

Context

  • Capital expenditures grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +842.5% toward the trailing-twelve-month pace of +958.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$10.75M+109.7% QoQ
Last fiscal yearDec 2025
-$2.9M+88.7% YoY
LTMMar 2026
-$21.33M+958.6% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+842.5%——
1 year+88.7%——
3-year CAGR-4.7%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(2.9M) USD
Year-over-year change
-88.7%

Capital Expenditures vs competitors

How CAPR compares with its peers on the latest reported figures

  • CAPR's LTM Mar 2026 capital expenditures of $21.33M is the 5th largest of the 10 companies compared; the peer median is $1.19M.
  • Its year-over-year change of +958.6% is the 2nd highest of 10, against a peer median of +43.1%.
  • Over three fiscal years its annual growth of -4.7% compares with a peer median of -19.2%.
CAPR Competitors Peer median
Capital Expenditures for CAPR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PTCTPTC Therapeutics, Inc.LTM Jun 2026$302.05M +1172.9%+25.3%29.9%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$71.85M +29.1%+36.8%7.5%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$69.14M -54.0%+46.8%3.2%
DYNDyne Therapeutics, Inc.LTM Jun 2026$21.4M +803.5%-14.5%—
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$21.33M +958.6%-4.7%—
SLDBSolid Biosciences Inc.LTM Mar 2026$1.19M +88.9%-27.4%—
WVEWave Life Sciences Ltd.LTM Mar 2026$981.99K +43.1%-19.2%1.4%
PEPGPepGen Inc.LTM Mar 2026$139K -75.6%-58.7%—
EWTXEdgewise Therapeutics, Inc.LTM Sep 2026$126K -72.4%-64.1%—
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$59K +101.7%-28.8%1.0%
Peer median (excluding CAPR) $1.19M+43.1%-19.2%3.2%

Competitors are the stored peer set for CAPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(20.02M)(29.02M)(22.29M)(40.47M)(105.04M)
Depreciation & Amortization245.7K533.13K1.07M1.43M1.89M
Deferred Income Tax(310.26K)0000
Stock-Based Compensation2.97M4.46M7.39M9.77M17.23M
Change in Working Capital182.34K28.75M(11.75M)(10.78M)12.2M
Accounts Receivables(391.75M)(155.83K)(9.82M)3.5K10.31M
Inventory391.75M0000
Accounts Payables991.17K1.21M1.33M1.94M5.98M
Other Working Capital(808.83K)27.7M(3.25M)(12.73M)(4.09M)
Other Non-Cash Items129.73K196.01K(18.24K)65.54K3.92M
Operating Cash Flow(16.81M)4.92M(25.6M)(40M)(69.81M)
Capital Expenditures(1.2M)(3.36M)(2.05M)(1.54M)(2.9M)
Acquisitions (Net)00000
Purchases of Investments0(114.22M)(97.44M)(208.44M)(151.39M)
Sales of Investments082.51M104.6M93.8M260.6M
Other Investing Activities00000
Investing Cash Flow(1.2M)(35.07M)5.11M(116.18M)97.48M
Debt Repayment00000
Common Stock Issued20.17M4.8M25.52M152.32M248.89M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities50.56K70.3K64.6K450.17K296
Financing Cash Flow20.23M4.87M25.58M152.77M248.89M
Effect of Forex Changes00000
Net Change in Cash2.22M(25.28M)5.09M(3.41M)276.56M
Free Cash Flow(18.01M)1.56M(27.64M)(41.53M)(72.72M)

Capricor Therapeutics, Inc.

NASDAQ:CAPR

Intrinsic Alpha fair value

Locked

Current Price

$8.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.